Home Healthcare Biotechnology CAR-T Cell Therapy Market

CAR-T Cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, Others), By Indication (Leukemia, Lymphoma, Multiple Myeloma, Autoimmune Disorders, Others), By End User (Hospitals, Cancer Care Treatment Centres, Academic & Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 29, 2026 | Author: Dhanashri B | Format: | Report Code: SR7885DR | Pages: 205
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. CAR-T Cell Therapy Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Abecma
    2. Breyanzi
    3. Kymriah
    4. Tecartus
    5. Yescarta
    6. Others
  2. CAR-T Cell Therapy Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Leukemia
    2. Lymphoma
    3. Multiple Myeloma
    4. Autoimmune Disorders
    5. Others
  3. CAR-T Cell Therapy Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Cancer Care Treatment Centres
    3. Academic & Research Institutes
  4. Regional CAR-T Cell Therapy Market
    1. North America
      1. North America CAR-T Cell Therapy Market By Product 2022-2034 (USD MILLION/ Units)
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
      2. North America CAR-T Cell Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Leukemia
        2. Lymphoma
        3. Multiple Myeloma
        4. Autoimmune Disorders
        5. Others
      3. North America CAR-T Cell Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Cancer Care Treatment Centres
        3. Academic & Research Institutes
      4. U.S.
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      5. Canada
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
    2. Europe
      1. Europe CAR-T Cell Therapy Market By Product 2022-2034 (USD MILLION/ Units)
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
      2. Europe CAR-T Cell Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Leukemia
        2. Lymphoma
        3. Multiple Myeloma
        4. Autoimmune Disorders
        5. Others
      3. Europe CAR-T Cell Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Cancer Care Treatment Centres
        3. Academic & Research Institutes
      4. U.K.
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      5. Germany
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      6. France
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      7. Spain
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      8. Italy
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      9. Russia
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      10. Nordic
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      11. Benelux
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      12. Rest of Europe
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
    3. APAC
      1. APAC CAR-T Cell Therapy Market By Product 2022-2034 (USD MILLION/ Units)
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
      2. APAC CAR-T Cell Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Leukemia
        2. Lymphoma
        3. Multiple Myeloma
        4. Autoimmune Disorders
        5. Others
      3. APAC CAR-T Cell Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Cancer Care Treatment Centres
        3. Academic & Research Institutes
      4. China
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      5. Korea
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      6. Japan
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      7. India
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      8. Australia
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      9. Taiwan
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      10. South East Asia
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      11. Rest of Asia-Pacific
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
    4. Middle East and Africa
      1. Middle East and Africa CAR-T Cell Therapy Market By Product 2022-2034 (USD MILLION/ Units)
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
      2. Middle East and Africa CAR-T Cell Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Leukemia
        2. Lymphoma
        3. Multiple Myeloma
        4. Autoimmune Disorders
        5. Others
      3. Middle East and Africa CAR-T Cell Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Cancer Care Treatment Centres
        3. Academic & Research Institutes
      4. UAE
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      5. Turkey
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      6. Saudi Arabia
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      7. South Africa
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      8. Egypt
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      9. Nigeria
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      10. Rest of MEA
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
    5. LATAM
      1. LATAM CAR-T Cell Therapy Market By Product 2022-2034 (USD MILLION/ Units)
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
      2. LATAM CAR-T Cell Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Leukemia
        2. Lymphoma
        3. Multiple Myeloma
        4. Autoimmune Disorders
        5. Others
      3. LATAM CAR-T Cell Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Cancer Care Treatment Centres
        3. Academic & Research Institutes
      4. Brazil
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      5. Mexico
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      6. Argentina
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      7. Chile
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      8. Colombia
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
      9. Rest of LATAM
        1. Abecma
        2. Breyanzi
        3. Kymriah
        4. Tecartus
        5. Yescarta
        6. Others
        7. Leukemia
        8. Lymphoma
        9. Multiple Myeloma
        10. Autoimmune Disorders
        11. Others
        12. Hospitals
        13. Cancer Care Treatment Centres
        14. Academic & Research Institutes
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.